Merck & Co. Overview
- Founded
- 1891
- Status
- Public
- Employees
- 71,000
- Stock Symbol
- MRK
- Investments
- 67
- Share Price
- $82.46
- (As of Wednesday Closing)
Merck & Co. General Information
Description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States.
Contact Information
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NYS
Primary Office
- 2000 Galloping Hill Road
- Kenilworth, NJ 07033
- United States
+1 (908) 000-0000
Merck & Co. Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $82.46 | $83.19 | $65.25 - $90.46 | $210B | 2.53B | 8.95M | $4.55 |
Merck & Co. Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
|---|---|---|---|---|
| EV | 229,673,547 | 249,714,258 | 212,235,768 | 169,355,061 |
| Revenue | 47,347,000 | 46,840,000 | 42,294,000 | 40,122,000 |
| EBITDA | 17,978,000 | 15,735,000 | 13,649,000 | 11,566,000 |
| Net Income | 11,517,000 | 9,843,000 | 6,220,000 | 2,394,000 |
| Total Assets | 89,800,000 | 84,397,000 | 82,637,000 | 87,872,000 |
| Total Debt | 28,741,000 | 26,346,000 | 25,114,000 | 24,410,000 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Merck & Co. Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Merck & Co.‘s full profile, request access.
Request a free trialMerck & Co. Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabo
Pharmaceuticals
Kenilworth, NJ
71,000
As of 2019
00000000
00000
tetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
0000000000000
Thousand Oaks, CA
00000
As of 0000
00.000
000000000000
00.000
000 0000
sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis no
0000 000000000
Indianapolis, IN
00000
As of 0000
000000 - 000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialMerck & Co. Competitors (60)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | 00000 | 00.000 | 000000000000 | 00.000 |
| 000 00000 | Corporation | Indianapolis, IN | 00000 | 000000 - 000 | ||
| 000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000&0 | |
| 0000000-00000 0000 | Corporation | New York, NY | 00000 | 00000 | 000000000 | 00000 |
| 00000000 | Corporation | Basel, Switzerland | 000000 | 000000000000 |
Merck & Co. Executive Team (72)
Merck & Co. Board Members (22)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000000 0000000 00 | Self | Board Member | 000 0000 |
| 0000 000000 | Merck & Co. | Board Member | 000 0000 |
| 00000 000000 | Self | Board Member | 000 0000 |
| 0000000 0000000 00 | Merck & Co. | Chief Executive Officer and Chairman of the Board | 000 0000 |
| 000000 0000 | Self | Board Member | 000 0000 |
Merck & Co. Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialMerck & Co. Investments & Acquisitions (67)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00 000000000000000 | 23-Dec-2020 | 000000000 | Drug Discovery | 00000 0000000000 00.0 | |
| 00000000 | 18-Dec-2020 | 000000000000000000 | 00.000 | Drug Discovery | 00000 0000000000 00.0 |
| 0000000000 | 23-Nov-2020 | 000000000000000000 | 00000 | Drug Discovery | 00000 0000000000 00.0 |
| 00000 000000 (0000 | 27-Jul-2020 | 000000000 00000 00 | 0000 | Buildings and Property | |
| Yumanity Therapeutics | 24-Jun-2020 | Later Stage VC | 000.00 | Drug Discovery | 00000 00000000 00.0 |
Merck & Co. Subsidiaries (20)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| VelosBio | Drug Discovery | San Diego, CA | 2017 |
| 00000 000000000000 | Biotechnology | Lexington, MA | 0000 |
| 0000000 0000000000 | Pharmaceuticals | Dallas, TX | 0000 |
| 00000 000000 00000 | Corporate Venture Capital | Kenilworth, NJ | 0000 |
| 0000000000 | Biotechnology | Australia | 0000 |
Merck & Co. Exits (23)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000000 000000000 | 24-Jun-2020 | 00000 00000 00 | 000.00 | Completed |
|
| 0000000 | 25-Jul-2018 | 00000 00000 00 | 00000 | Completed |
|
| 00000000 0000 0000 | 01-Aug-2016 | 00000 00000 00 | 0000 | Completed |
|
| 0000000 | 07-Jan-2016 | 00000 00000 00 | 000.00 | Completed |
|
| Quartet Medicine | 06-Jan-2016 | Corporate | 0000 | Completed |